Takeda Pharmaceutical Company (4502) 44th Annual J.P. Morgan Healthcare Conference summary

Strategic transformation, vision, and innovation

• Shifted from generics and OTC to an innovation-driven pharmaceutical business, emphasizing digital, cloud, and AI across all operations.

• Committed to life-transforming treatments guided by patient, people, and planet values, prioritizing patient, trust, reputation, and business.

• U.S. revenue share grew from under 20% to 52%, with operations in 80 countries and $5B annual R&D investment.

• R&D now focused on gastroenterology, neuroscience, and oncology, with reduced generic exposure expected until 2030+.

• Leadership transition planned, with Julie Kim succeeding Christophe Weber as CEO.

Pipeline and product launches

• Eight late-stage assets targeted for launch before 2030, many with breakthrough or orphan status and significant lifecycle management opportunities.

• Strategic partnership with Innovent added TAK-928 (immuno-oncology) and TAK-921 (Claudin 18.2 ADC) to the pipeline.

• Three major launches—Oveporexton, Rusfertide, and Zasocitinib—planned within the next 18 months, pending regulatory approval.

• Fazirsiran (RNA therapy for liver disease) and mezagitamab (CD38 antibody) also advancing.

• Several assets have received breakthrough, fast track, or orphan drug designations.

Clinical data and market potential

• Oveporexton exceeded phase III expectations, normalizing symptoms in a significant majority of NT1 patients with strong safety and tolerability; launch expected H2 2026.

• Rusfertide offers durable hematocrit control and reduced phlebotomy eligibility in polycythemia vera, targeting ~155k diagnosed U.S. patients.

• Zasocitinib met all primary and secondary endpoints in Phase 3 for plaque psoriasis, with high efficacy and a favorable safety profile, aiming to double the oral therapy market.

• Combined peak revenue potential for the three products estimated at $6B–$10B, offsetting ENTYVIO's expected decline post-2030.

• Five additional late-stage assets to further support growth before 2030.